Defence Therapeutics Announces Exciting Breakthrough

The treatment of cancer has taken some huge strides forward over the past few decades, but more effective solutions are still urgently needed for a variety of clinical needs. Fortunately, Defence Therapeutics (CSE: DTC, FSE: DTC, OTC: DTCFF), a Canadian biotech innovator, is offering hope.

Defence Therapeutics is working to develop next generation therapies to combat various types of cancer, as well as a variety of deadly infectious diseases like Covid, through the development of vaccines using their proprietary ACCUM technology. The ACCUM technology enables a more precise and effective delivery of critical drugs to target cells and can optimize the efficacy of treatments by up to 200%. Given this kind of potential, ACCUM could change the standard of care, and create a huge market impact.

Defence Therapeutics has set out to solve a stubborn problem when it comes to targeted therapies. In most cases, the efficacy of bio drugs falls short because of difficulties reaching intracellular sites. The ACCUM delivery platform, on the other hand, helps drugs bypass these barriers so they can successfully reach and accumulate in target cells to greatly enhance therapeutic potency. 

The development of intracellular delivery platforms is nothing new. Several companies, including Sapreme Technologies, PCI Biotech (OSE: PCIB), and Feldan Therapeutics are actively pursuing their own solutions, however most of them are incapable of reaching specific target cells. The ACCUM platform can, which is why Defence Therapeutics claims its platform holds a 10-fold advantage over their competition.

While the ACCUM technology is already proving its potential in laboratory tests, it’s the platform’s versatility that really has Defence Therapeutics excited. ACCUM can be attached to DNA, RNA, proteins, antigens, antibodies and virtually any kind of bio drug. “I personally call ACCUM a solution looking for a problem,” Dr. Moutih Rafei, VP Research & Director at Defence Therapeutics said. “Usually when you have a company that has a drug or a specific product, that product is intended for one target, one indication. The beauty of the ACCUM technology, is that it's extremely versatile. You can attach it to any biomolecule. Any company that has a vaccine, an antibody or even a drug that they want to insert into a cell can benefit from the ACCUM technology.” 

This versatility is a big reason why Defence Therapeutics has chosen to focus significant resources on the development of mRNA vaccines. Compared to other modalities, mRNA vaccines offer tremendous advantages. They can be manufactured very quickly - the recent development of Covid-19 vaccines is an excellent casein point - and they are relatively inexpensive.

But the development of mRNA vaccines does have its challenges. mRNA vaccines are not as stable or as potent as protein-based vaccines, and these limitations have prevented mRNA vaccines from reaching their full potential, until recently.  

This past April, Defence Therapeutics announced they had realized a significant break through when they successfully developed and optimized a process to conjugate, or attach, mRNA molecules to their ACCUM delivery platform. This exciting advancement elevates the hope for new and more potent mRNA vaccines.

The effectiveness of Defence Therapeutic’s mRNA conjugation process will be validated in trials starting later in 2023. These trials will compare their process to "naked" mRNA vaccines administered to immunocompetent mice. If all goes as expected, Defence Therapeutics could soon be looking at an immense opportunity. The mRNA therapeutics market alone is expected to surpass $128 billion by 2030 with an annual growth rate in the range of 13% over the next seven years, according to Precedence Research. 

“The market is huge”, Dr. Rafei confirmed. “When you look at immuno-oncology, we're talking billions of dollars, and the market is going to keep on expanding because of an aging society, and the high increase in cancers.”

Generally, it takes up to 10 years to commercialize a therapeutic product. Defence Therapeutics estimates that it will take about seven years for their first products to reach market. But that hasn’t stopped the company from actively working to license its products to other pharmaceutical companies. “This will be significant, specifically for companies that have products that have shown moderate or poor efficacy in clinical trials,” Dr. Rafei declared. “It could be a way to make these drugs more potent.”

The exciting accomplishments of the last few months have brought Defence Therapeutics to an inflection point that could significantly affect the future development and growth of the company, and you can bet the big players in the industry will be watching closely.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

_{FULL DISCLOSURE: Defence Therapeutics Inc. is a client of BTV-Business Television. This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional. Any action taken as a result of reading information here is the reader’s sole responsibility.}‍